Home » Topics » BioWorld Science, Infection

BioWorld Science, Infection
RSS

Thapsigargin shows broad-spectrum activity against respiratory viruses including SARS-CoV-2

Feb. 5, 2021

New research suggests COVID-19 antibodies persist at least 6 months

Feb. 5, 2021

Positive preliminary phase I data for iNKT cell therapy in patients with COVID1-9

Feb. 5, 2021

Staidson (Beijing) Biopharmaceuticals patents antibodies targeting Pseudomonas PcrV

Feb. 5, 2021

New NMT inhibitors discovered at CSPC Zhongqi Pharmaceutical Technology

Feb. 5, 2021

Corvus initiates phase III study of CPI-006 hospitalized patients with COVID-19

Feb. 5, 2021

Immunome establishes partnership to advance IMM-BCP-01 for COVID-19

Feb. 5, 2021

New dengue virus inhibitor shows preclinical promise

Feb. 4, 2021

Preliminary phase I data show safety and immunogenicity of VXA-CoV2-1 oral tablet vaccine

Feb. 4, 2021

Positive topline data from phase II study of Allocetra in severe and critical COVID-19

Feb. 4, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...